Biobase. Cc

Lab Reagents

Biobase Lab Instruments Laboratories manufactures the www. biobase. cc reagents distributed by Genprice. The Www. Biobase. Cc reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Biobase lab Instruments. Other Www. products are available in stock. Specificity: Www. Category: Biobase. Group: Cc

Cc information

CC-90003
B2419-5 each
EUR 496.8

CC-115
B2499-25 each
EUR 757.2

CC-115
B2499-5 each
EUR 235.2

PDGF CC protein
30R-AP043 20 ug
EUR 327.6
Description: Purified recombinant Human PDGF CC protein

CC-401 hydrochloride
A3287-10 10 mg
EUR 645.6
Description: CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.

CC-401 hydrochloride
A3287-5 5 mg
EUR 385.2
Description: CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.

CC-401 hydrochloride
A3287-5.1 10 mM (in 1mL DMSO)
EUR 417.6
Description: CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.

CC-401 hydrochloride
A3287-50 50 mg
EUR 1796.4
Description: CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.

Lenalidomide (CC-5013)
A4211-100 100 mg
EUR 226.8
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects.

Lenalidomide (CC-5013)
A4211-250 250 mg
EUR 268.8
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects.

Lenalidomide (CC-5013)
A4211-5.1 10 mM (in 1mL DMSO)
EUR 135.6
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects.

Lenalidomide (CC-5013)
A4211-50 50 mg
EUR 184.8
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects.

Lenalidomide (CC-5013)
A4211-500 500 mg
EUR 309.6
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects.

Lenalidomide (CC-5013)
A4211-S Evaluation Sample
EUR 97.2
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects.

Pomalidomide (CC-4047)
A4212-10 10 mg
EUR 170.4
Description: Pomalidomide, previously known as CC-4047 or actimid, is a potent immunomodulatory molecule that exhibits antineoplastic activity for the treatment of hematological malignancies, especially relapsed and refractory multiple myeloma (MM).

Pomalidomide (CC-4047)
A4212-200 200 mg
EUR 964.8
Description: Pomalidomide, previously known as CC-4047 or actimid, is a potent immunomodulatory molecule that exhibits antineoplastic activity for the treatment of hematological malignancies, especially relapsed and refractory multiple myeloma (MM).

Pomalidomide (CC-4047)
A4212-5 5 mg
EUR 129.6
Description: Pomalidomide, previously known as CC-4047 or actimid, is a potent immunomodulatory molecule that exhibits antineoplastic activity for the treatment of hematological malignancies, especially relapsed and refractory multiple myeloma (MM).